DRREDDY1,141.00

Dr. Reddy's Laboratories Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLALUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹95,274 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity19.7416.6710.9810.98
Return on Assets14.3511.587.157.15
Return on Capital Employed22.0818.8010.6210.62
Return on Invested Capital20.1815.308.646.07
Margins
EBITDA Margin28.3226.1819.1515.47
Operating Margin23.0720.9613.0413.04
Incremental Operating Margin8.21-231.82
Pretax Margin25.6623.4615.9612.12
Net Income Margin19.9117.5412.349.58
Net Income to Common Margin0.0017.3212.459.70
FCF Margin6.433.695.445.44
Additional
Effective Tax Rate22.5925.5222.9621.30
Dvd Payout Ratio11.9211.6416.02
Sustainable Growth Rate17.3914.739.2210.98
Incremental Operating Margin %8.21-231.82290.96
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.